

ASX Release

SUDA LTD BUSINESS DEVELOPMENT UPDATE

PERTH, AUSTRALIA – 19 April 2016: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces an update on its business development activities. The Company is in advanced negotiations with multiple pharmaceutical companies regarding licensing its first-in-class oral sprays in a variety of countries. Subject to successful contract negotiations, SUDA aims to finalise agreements within the next few months. Discussions with philanthropic groups and other providers of non-dilutive funding for a second Phase III study of ArTiMist™ in paediatric malaria are also progressing.

The business development team attended the BIO-Europe Spring international partnering conference, which was held in Stockholm, Sweden, on 4-6 April 2016. The team had one-to-one meetings with over 30 pharmaceutical companies. These included several prospective partners that have completed their due diligence and with whom SUDA is negotiating financial terms for a license in various territories.

SUDA also had productive meetings this month with global health philanthropic groups and the Medicines for Malaria Venture to discuss SUDA's ArTiMist™ sublingual anti-malarial spray. The objective of these discussions was to secure funding for the Phase III trial of ArTiMist™ as an early interventional treatment of paediatric malaria in the pre-referral setting. In addition, the Company met with the World Health Organisation to update the Global Malaria Program members and to discuss its plans regarding ArTiMist™.

Commenting on SUDA's business development progress, Mr Stephen Carter, Chief Executive Officer of SUDA said: "This is an exciting period for SUDA. Our investment in the development of novel oral sprays where there is a real need for improved treatments has been recognised by the pharmaceutical industry. I am pleased by the progress of our business development activities and look forward to finalising a series of licensing deals in the coming months. In addition, the interest in ArTiMist™ from pharmaceutical companies and philanthropic groups continues to grow as we seek to expand the use of the product to include treatment of paediatric malaria in the pre-referral setting."



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au